dr bennett's semaglutide Health Canada's market authorisation for our generic Injection makes us the first company to receive this authorisation in Canada. This milestone reflects our deep focus on complex generics and peptide based Dr. Stephen Bennett, MD |

Wegovy clinical studies and reported hair loss percentages Wegovy clinical trials show more notable results: Hair loss affected 3% of adult participants compared to 1% in the placebo group [7] The numbers were higher in children 12 and older, where 4% reported hair loss while the placebo group showed no cases [8] Comparing hair loss rates across different GLP-1 medications GLP-1 medications of all types show distinct patterns: Tirzepatide (Mounjaro): Users reported hair loss rates between 4.9% to 5.7% at doses from 5mg to 15mg [8] Zepbound: The overall rates reached 4% to 5%, with women showing much higher numbers 7.1% compared to just 0.5% in men [8] Research from the University of British Columbia shows that people who use semaglutide have a 52% higher chance of hair loss compared to those taking older weight loss medications [9]

Our team of registered dietitians focus on realistic, everyday changes that improve your relationship with food and support long-term health

How Good is the Combination of Vitamin C and Glutathione

Mouse microbiota models: comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria

36 CespuglioR.AmrouniD.MeillerA.BuguetA.Gautier-SauvignS